Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 30 versus FOCALIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 30 versus FOCALIN XR.
ADDERALL XR 30 vs FOCALIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR is a central nervous system (CNS) stimulant. It contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, leading to increased synaptic concentrations. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully understood but is thought to involve activation of dopaminergic and noradrenergic pathways in the prefrontal cortex.
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
20-60 mg orally once daily in the morning; start at 20 mg once daily, titrate by 10 mg weekly based on tolerability and response.
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
None Documented
None Documented
The terminal elimination half-life is 10–13 hours for dextroamphetamine (the more active enantiomer) in adults; for the racemic mixture (dextroamphetamine/amphetamine), the half-life is shorter (6–8 hours) due to differential metabolism. Clinical context: Steady-state achieved within 2–3 days; once-daily dosing is sufficient.
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Renal: approximately 90% (30–40% unchanged, remainder as metabolites including dehydroamphetamine and hydroxylated metabolites). Fecal: <4%. Biliary: minimal.
Renal (approximately 90% as unchanged drug and metabolites)
Category C
Category C
CNS Stimulant
CNS Stimulant